Skip to main content

Advertisement

SpringerLink
Log in

Retrospective analysis of the effects of low-dose, high frequency human growth hormone on serum lipids and prostate specific antigen

  • Published:
Journal of the American Aging Association Aims and scope Submit manuscript

Abstract

Background. Elevated serum total cholesterol (TC) and triglycerides (TG) are risk factors for atherosclerosis and ischemic heart disease. Adult growth hormone deficiency (AGHD) is associated with elevated TC and TG. Many treatment protocols for AGHD use relatively high doses of growth hormone (GH) given at low frequency, which is associated with increased incidences of edema, joint pains, and carpal tunnel syndrome. We have treated > 2200 patients using a low-dose high frequency (LDHF) dosing regimen of GH which results in similar beneficial subjective responses, and fewer of the side-effects associated with the higher-dosage treatment at a substantial cost savings. Clinically, in addition to increased insulin-like growth factor I (IGF-I), we observed lower TG and TC levels and no elevation of prostate specific antigen levels in treated patients.

Methods. A retrospective analysis of IGF-I, TG, TC, and PSA data from our patient population was performed to test our hypothesis that positive objective responses of IGF-I, TG, and TC occur and that elevation of PSA does not occur in response to LDHF dosing regimen of GH. The mean duration of treatment of the analyzed data ranged from 181 to 259 days.

Results. The mean plasma IGF-I level rose significantly (p<.00001) to a level 37% greater than baseline with treatment. TC and TG decreased significantly (p<.001) in those patients with elevated baseline values, and did not change significantly in those with normal baseline values. PSA concentrations decreased non-significantly during treatment, and few cases of edema, joint pain, or carpal tunnel were reported.

Conclusions. Treatment of AGHD using the LDHF dosing regimen of GH resulted in significant increases in IGF-I, significant reductions in TC and TG levels in patients with elevated baseline values, no increase in PSA concentrations, and fewer side effects than other dosing regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bierman, EL: Atherosclerosis and other forms of arteriosclerosis, in Harrison’s Principles of Internal Medicine, edn 12, edited by Wilson, JD, Braunwald, E, et al, New York, McGraw-Hill, Inc, 1991, pp. 996–998.

    Google Scholar 

  2. Carroll, PV, Christ, ER, Bengtsson BA, et al: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. J. Clin. Endocrinol. Metab., 83:382–395, 1997.

    Article  Google Scholar 

  3. Attanasio, AF, Lamberts, SWJ, Matranga, AMC, et al: Adult growth hormone-deficient patients demonstrate heterogenity between childhood onset and adult onset before and during human GH treatment. J. Clin. Endocrinol. Metab., 82:82–88, 1997.

    Article  PubMed  CAS  Google Scholar 

  4. De Boer, H, Blok, GJ, Voerman, HJ, Phillips, M, and Schouten, JA: Serum lipid levels in growth hormone-deficient men. Metab. Clin. Exp., 43:199–203, 1994.

    PubMed  Google Scholar 

  5. Cuneo, RC, Salomon, F, Watts, GF, Hesp, R, and Sonksen, PH: Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metab. Clin. Exp., 42:1519–1523, 1993.

    PubMed  CAS  Google Scholar 

  6. Rosen, T, Eden, S, Larson, G, Wilhelmsen, L, and Bengtsson, BA: Cardiovascular risk factors in adult patients with growth hormone deficiency. ACTA Endocrinol. (Copenh)., 129:195–200, 1993.

    CAS  Google Scholar 

  7. Johansson, JO, Landin, K, Tengborn, L, Rosen, T, and Bengtsson, BA: High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb., 14:434–437, 1994.

    PubMed  CAS  Google Scholar 

  8. Salomon, F, Cuneo, RD, Hesp, R, and Sonksen, PH: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med., 321: 1797–1803, 1989.

    Article  PubMed  CAS  Google Scholar 

  9. Russell-Jones, DL, Watts, GF, Weissberger, A, et al: The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin. Endocrinol., (Oxf) 41:345–350, 1994.

    CAS  Google Scholar 

  10. Beshyah, SA, Henderson, A, Niththyananthan, R, et al: The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J. Clin. Endocrinol. Metab., 80:356–363, 1995.

    Article  PubMed  CAS  Google Scholar 

  11. Weaver, JU, Monson, JP, Noonan, K, et al: The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults. J. Clin. Endocrinol. Metab., 80:153–159, 1995.

    Article  PubMed  CAS  Google Scholar 

  12. Eden, S, Wiklund, O, Oscarsson, J, Rosen, T, and Bengtsson, BA: Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler. Thromb., 13:296–301, 1993.

    PubMed  CAS  Google Scholar 

  13. Rudman, D, Feller, AG, Nagraj, S, Hoskote, S, et al: Effects of human growth hormone in men over 60 years old. N. Engl. J. Med., 3231–6, 1990.

  14. Terry, LC, and Chein, E: Human growth hormone replacement therapy in aging adults at the Palm Springs Life Extension Institute, in Growing Young With HGH, edited by Klatz, R, New York, Harper Collins, 1997, pp. 62–73.

    Google Scholar 

  15. Svensson J, Bengtsson B, Taskinen M, Wiklund O, Johannsson G A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. Growth Horm IGF Res 2000 Jun;10(3):118–126

    Article  PubMed  CAS  Google Scholar 

  16. Chan, JM, Stampfer, J, Meir, J, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279:563–565, 1998.

    Article  PubMed  CAS  Google Scholar 

  17. Bozzola, M, Valtorta, A, Moretta A, et al: In vitro and in vivo effect of growth hormone on cytotoxic activity. J. Pediatr., 117:596–602, 1990.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Palm Springs Life Extension Institute, 2815 Tahquitz Cyn. Blvd. Bldg. A, Palm Springs, CA, 92262

    Edmund Chein M.D., J.D.

  2. University of Puerto Rico, Medical Sciences Campus, School of Public Helth, P.O. Box 365067, San Juan, Puerto Rico, 00936-507

    Michael J. Gonzalez D.Sc., Ph.D., FACN

  3. The Aidan Clinic, 621 S. 48th St. Bldg 111, Tempe, AZ, 85281

    Neil H. Riordan PA-C, M.S.

Authors
  1. Edmund Chein M.D., J.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Gonzalez D.Sc., Ph.D., FACN
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neil H. Riordan PA-C, M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Chein, E., Gonzalez, M.J. & Riordan, N.H. Retrospective analysis of the effects of low-dose, high frequency human growth hormone on serum lipids and prostate specific antigen. AGE 24, 59–62 (2001). https://doi.org/10.1007/s11357-001-0008-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11357-001-0008-2

Keywords

Search

Navigation